AbbVie

AL.com reports Howard Jacob is leaving the HudsonAlpha Institute for Biotechnology after three years there.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.

The partners will use population genomics to discover and develop novel therapeutics and companion diagnostics for a range of chronic diseases.

Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.